Lexaria Bioscience -

NASDAQ:LEXX; NASDAQ WARRANT:LEXXW

Home
About
Technology
Licensing Opportunities
Investors

Management

Lexaria Bioscience → Management

CFO

Michael Shankman, CPA

CEO

Richard Christopher

President and Chief Scientific Officer

John Docherty

Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
[email protected]

Canadian Operations
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

US Operations
105 Peach State Court, Suite A
Tyrone, GA 30290

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright © 2024 Lexaria Bioscience. All rights reserved.